Login to Your Account

Clinic Roundup

Tuesday, August 7, 2012

• Oxigene Inc., of Waltham, Mass., passed an interim toxicity analysis in its Phase II trial of Zybrestat (fosbretabulin tromethamine) and bevacizumab for ovarian cancer. Patients were randomized to receive bevacizumab 15 mg/kg I.V. or bevacizumab plus fosbretabulin tromethamine 60 mg/m2 I.V.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription